Verve Therapeutics Ownership | Who Owns Verve Therapeutics?
Verve Therapeutics Ownership Summary
Verve Therapeutics is owned by 91.55% institutional investors, 1.78% insiders, and 6.67% retail investors. Alphabet is the largest institutional shareholder, holding 14.85% of VERV shares. ARK Genomic Revolution is the top mutual fund, with 2.92% of its assets in Verve Therapeutics shares.
VERV Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Verve Therapeutics | 91.55% | 1.78% | 6.67% |
| Sector | Healthcare Stocks | 47.38% | 7.99% | 44.63% |
| Industry | Biotech Stocks | 45.43% | 7.81% | 46.75% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Alphabet | 12.35M | 14.85% | $60.26M |
| Blackrock | 6.62M | 7.96% | $32.31M |
| Vanguard group | 5.26M | 6.33% | $25.69M |
| T. rowe price investment management | 4.53M | 5.45% | $22.10M |
| State street | 3.35M | 4.03% | $16.35M |
| Casdin capital | 3.06M | 3.68% | $14.93M |
| Novo | 2.40M | 2.89% | $11.71M |
| Arch venture management | 2.01M | 2.42% | $9.80M |
| Baker bros. advisors lp | 1.69M | 2.03% | $8.25M |
| Jpmorgan chase | 1.69M | 2.03% | $8.25M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Arch venture management | 2.01M | 3.69% | $9.80M |
| Alphabet | 12.35M | 3.05% | $60.26M |
| Casdin capital | 3.06M | 1.14% | $14.93M |
| Novo | 2.40M | 0.59% | $11.71M |
| Redmile group | 1.46M | 0.43% | $7.14M |
| Palo alto investors lp | 575.82K | 0.33% | $2.81M |
| Ecor1 capital | 1.25M | 0.19% | $6.10M |
| Vestal point capital, lp | 500.00K | 0.18% | $2.44M |
| Pdt partners | 333.86K | 0.15% | $1.63M |
| Baker bros. advisors lp | 1.69M | 0.11% | $8.25M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 6.62M | 0.00% | 1.25M |
| Jacobs levy equity management | 905.82K | 0.02% | 905.82K |
| Vestal point capital, lp | 500.00K | 0.18% | 500.00K |
| Goldman sachs group | 1.29M | 0.00% | 457.38K |
| Novo | 2.40M | 0.59% | 400.00K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ark investment management | - | - | -2.94M |
| Federated hermes | 1.15M | 0.01% | -2.41M |
| Fmr | 1.42M | 0.00% | -1.96M |
| State street | 3.35M | 0.00% | -1.75M |
| Nikko asset management americas | - | - | -1.12M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Jacobs levy equity management | 905.82K | 0.02% | 905.82K | $4.42M |
| Vestal point capital, lp | 500.00K | 0.18% | 500.00K | $2.44M |
| Los angeles capital management | 242.47K | 0.00% | 242.47K | $1.18M |
| Gsa capital partners llp | 203.68K | 0.07% | 203.68K | $994.00K |
| Mirae asset global etfs | 144.03K | 0.00% | 144.03K | $702.18K |
Sold Out
| Holder | Change |
|---|---|
| Financial gravity asset management | -3.00 |
| Nelson, van denburg & campbell wealth management group | -11.00 |
| Riggs asset managment | -22.00 |
| Hollencrest capital management | -53.00 |
| Entrypoint capital | -92.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2024 | 165 | - | 76,110,149 | -6.75% | 91 | 0.95% | 96 | -4.95% | 46 | 15.00% |
| Mar 31, 2024 | 165 | 2.48% | 81,620,773 | 9.25% | 98 | 0.85% | 101 | -8.18% | 40 | 60.00% |
| Dec 31, 2023 | 161 | 13.38% | 74,711,879 | 16.98% | 107 | 1.05% | 110 | 25.00% | 25 | 8.70% |
| Sep 30, 2023 | 142 | 13.60% | 63,865,080 | 3.21% | 101 | 1.01% | 88 | 39.68% | 23 | -39.47% |
| Jun 30, 2023 | 125 | -0.79% | 61,879,660 | -2.20% | 99 | 0.95% | 63 | - | 38 | 11.76% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| ARK Genomic Revolution | 2.47M | 2.92% | -340.12K |
| SPDR® S&P Biotech ETF | 2.33M | 2.75% | 25.74K |
| Vanguard Total Stock Mkt Idx Inv | 2.15M | 2.55% | - |
| iShares Russell 2000 ETF | 1.83M | 2.16% | -4.12K |
| T. Rowe Price Small-Cap Value | 1.24M | 1.47% | -38.25K |
| Vanguard Institutional Extnd Mkt Idx Tr | 986.56K | 1.17% | 15.92K |
| T. Rowe Price US Small-Cap Core Equity | 910.26K | 1.08% | -41.87K |
| CREF Stock R1 | 868.91K | 1.03% | 175.51K |
| Vanguard Small Cap Index | 850.11K | 1.00% | 2.01K |
| Fidelity Small Cap Index | 730.55K | 0.86% | -16.16K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 14, 2024 | Ashe Andrew D. | See Remarks | Buy | $475.76K |
| Apr 02, 2024 | Nickerson Joan | Chief Administrative Officer | Sell | $12.48K |
| Dec 01, 2023 | Yeshwant Krishna | Buy | $18.00M | |
| Nov 29, 2023 | Dorval Allison | Chief Financial Officer | Sell | $6.34K |
| Dec 01, 2022 | Bellinger Andrew | CSO & CMO | Sell | $19.85K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2024 Q2 | 1 | 1 |
| 2024 Q1 | - | - |
| 2023 Q4 | 1 | 1 |
| 2023 Q3 | - | - |
| 2023 Q2 | - | - |
VERV Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools